Hoppe JB, Coradini K, Frozza RL, Oliveira CM, Meneghetti AB, Bernardi A, et al
GLP-1 receptor agonists such as semaglutide (marketed under brand names Ozempic, Wegovy, and Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (marketed under brand names Mounjaro and Zepbound) are FDA-approved prescription medications for specific uses in type 2 diabetes management and, in some cases, chronic weight management
your clinician reviews their current regulatory status with you before prescribing
For semaglutide (Wegovy), the typical starting dose is 0.25 mg weekly, with increases every four weeks until reaching the maintenance dose of 2.4 mg weekly (or 1.7 mg if the higher dose is not tolerated)
A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients taking another diabetes medication, DPP-4 inhibitors
Vitamin B12 is involved in energy production in your body